Roquefort Therapeutics today announced the signing of a term sheet for its Midkine antibody portfolio to PDC FZ-LLC (PDC), a member of the PDC-CRO group headquartered in Dubai and with a track record of over 150 clinical trials. PDC will develop one or more of the Midkine antibodies within a new Special Purpose Vehicle (SPV) to complete one Phase 1 clinical trial within three years and then seek a trade sale of the SPV. The term sheet is non-binding, except for certain provisions including exclu ....
